Seattle Reproductive Medicine Joins the Personalized Reproductive Medicine (PReM) Initiative

Seattle Reproductive Medicine Joins the Personalized Reproductive Medicine (PReM) Initiative

The largest fertility clinic in the Pacific Northwest is the latest to join the alliance founded by next-generation women's health company Celmatix to decode fertility potential

NEW YORK, May 16, 2018 /PRNewswire-PRWeb/ -- Today, Celmatix, the next-generation women's health company, announced that it has welcomed Seattle Reproductive Medicine (SRM) into the Personalized Reproductive Medicine (PReM) Initiative. Initially launched in 2015, the PReM network brings together world-renowned academic institutions such as Stanford Medicine Fertility and Reproductive Health Services and Yale Fertility Center, alongside several of the most highly regarded private fertility treatment centers, to help move the field of reproductive health closer to the personalized and precision medicine paradigms already standard of care in fields like oncology. Seattle Reproductive Medicine is the largest fertility clinic in the Pacific Northwest, making it a natural partner for this unprecedented consortium.

"The precision medicine revolution in reproductive health has begun and the PReM Initiative is leading the charge," said Piraye Yurttas Beim, PhD, CEO and founder of Celmatix. "We launched the PReM initiative to apply the playbook that's been so effective in oncology and other areas of medicine to this relatively under-served--yet critical--area of health. SRM has been a member of our Polaris Data Network for years, and we have had the pleasure of co-authoring several key studies with them leveraging their vast, de-identified electronic health record datasets. We are excited to now also partner with them on genomics research as well. They bring to the consortium not only thought leadership but also help us make sure that patients in the Pacific Northwest will be represented in the important reference datasets that are now powering the genomic revolution in our field."

This collaboration marks one of the first taken on by the new Research Committee launched by Seattle Reproductive Medicine at the beginning of this year. Research has been a part of the SRM story since its founding. Before launching the clinic in 2004, the physician group was in academic medicine at the University of Washington (UW), where they received several National Institutes of Health grants and helped to make groundbreaking discoveries on reproductive aging. At Seattle Reproductive Medicine, these doctors have continued their research endeavors to learn more about infertility, reproductive aging, and treatment options to better serve current and future patients.

"This is the future of reproductive medicine, where the trend is towards personalized medicine as a general care tool. As a researcher and clinician, I like the idea of being able to contribute to the Personalized Reproductive Medicine Initiative," said Gerard S. Letterie, DO, SRM. "By learning more about risk factors, patients can begin to be preemptive about their care."

"We are thrilled to build on our existing partnership with Celmatix by joining the PReM initiative," said Sara Mooney, Chair of the SRM Research Committee. "Being part of such a widespread and prestigious network really increases our ability to achieve meaningful outcomes with our research, which is our organization's primary goal."

Insights uncovered by the PReM initiative have the potential to revolutionize how fertility difficulties are diagnosed, treated, and eventually prevented. For more information on the PReM Initiative and to see a full list of partnering organizations, please visit

About Celmatix Inc.
Celmatix is a next-generation women's health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them and their physicians with more personalized information. The company's research-driven products include the Fertilome® test, the world's first multigene panel test that reveals what a woman's DNA says about her reproductive health, and Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience.

SOURCE Celmatix